3 Stocks to Buy According to Devesh Gandhi’s SilverArc Capital

In this article, we will discuss the top 3 stocks to buy according to Devesh Gandhi’s SilverArc Capital. If you want to read our detailed analysis of Gandhi’s history, investment philosophy, and hedge fund performance, go directly to the 8 Stocks to Buy According to Devesh Gandhi’s SilverArc Capital.

3. Veracyte, Inc. (NASDAQ:VCYT)

SilverArc Capital’s Stake Value: $11.7 million

Veracyte Inc. (NASDAQ:VCYT) is a genomic diagnostics company and has a product portfolio with products such as Afirma analysis, Percepta, Envisia, and others.

In the Q2 2021 investor letter, Artisan Partners mentioned Veracyte, Inc. (NASDAQ: VCYT). Here is what the fund said:

“Among our bottom contributors (includes) Veracyte. Veracyte develops and markets molecular tests designed to minimize ambiguity in the treatment of patients with cancer. These tests can reduce unnecessary surgeries and help put cancer patients at ease when the decision is to “watch and wait.” Shares have been pressured amid a recent investment cycle (acquired Decipher and HalioDX) and a resurgence of the pandemic earlier this year weighing on testing volumes. In addition, the company’s founder and CEO recently announced she was moving to Executive Chair. Her replacement is the former CFO of Illumina, who is very knowledgeable in invitro diagnostics and played a critical role in Illumina’s international expansion efforts (which we expect him to pursue at Veracyte). We are maintaining our position as patients return to the clinic for testing and as management executes on its strong R&D pipeline, including the upcoming launch of a nasal swab lung cancer test. Longer-term, the company is well-positioned to expand internationally as it ports its growing menu of tests onto the recently acquired nCounter instrument.”